TGFβ inhibitors in combination with anti-PD1 mAbs demonstrated CD8+ T-cell infiltration and improved tumour control in a subset of urothelial cancer patients and poorly immunogenic breast cancer models [71, 91]. Here, TGFB1 is linked to breast carcinoma.